Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia

• Published in: Journal of the American College of Cardiology Vol. 62; no. 13; pp. 1154 - 1162
• Main Authors: Ballantyne, Christie M., Davidson, Michael H., MacDougall, Diane E., Bays, Harold E., DiCarlo, Lorenzo A., Rosenberg, Noah L., Margulies, Janice, Newton, Roger S.
• Format: Journal Article
• Language: English
• Published: New York Elsevier Inc 24.09.2013; Elsevier Limited
• Subjects: Blood pressure; Cardiology; Cardiovascular; Cardiovascular disease; Cholesterol; Disease control; Drug dosages; Fatty acids; Insulin; Kinases; Lipids; Lipoproteins; low-density lipoprotein cholesterol; Medical laboratories; prevention; Proteins; Risk factors; Sterols; Studies; Triglycerides; HDL-C; cardiovascular disease; apo; risk factors; LDL-C; low-density lipoprotein cholesterol; ULN; hsCRP; AMPK; ACL; prevention; mITT; apolipoprotein; high-sensitivity C-reactive protein; adenosine triphosphate-citrate lyase; upper limit of normal; high-density lipoprotein cholesterol; adenosine monophosphate-activated protein kinase; modified intent-to-treat

The aim of this study was to assess the lipid-altering efficacy and safety of ETC-1002 in subjects with hypercholesterolemia. ETC-1002 is a small molecule that modulates pathways of cholesterol, fatty acid, and carbohydrate metabolism and may have therapeutic benefits in treating hypercholesterolemi...